Loading...
XETRGXI
Market cap2.43bUSD
Dec 23, Last price  
70.00EUR
1D
3.47%
1Q
-28.17%
Jan 2017
-0.86%
IPO
82.29%
Name

Gerresheimer AG

Chart & Performance

D1W1MN
XETR:GXI chart
P/E
20.14
P/S
1.17
EPS
3.48
Div Yield, %
1.94%
Shrs. gr., 5y
1.20%
Rev. gr., 5y
7.79%
Revenues
1.99b
+9.54%
00957,700,0001,060,103,0001,000,227,0001,024,804,0001,094,681,0001,219,068,0001,265,931,0001,290,016,0001,377,232,0001,375,460,0001,348,255,0001,367,730,0001,392,255,0001,418,786,0001,498,007,0001,817,094,0001,990,486,000
Net income
116m
+20.81%
00-1,228,0004,510,0006,962,00046,747,00054,428,00060,191,00062,155,00066,336,000104,217,000121,638,000100,887,000128,965,00080,781,00088,559,00083,788,00096,120,000116,126,000
CFO
294m
+32.62%
36,821,00054,747,00054,108,000165,333,000117,466,000159,787,000129,747,000173,566,000146,676,000158,286,000203,776,000173,487,000219,163,000173,472,000192,924,000222,194,000212,076,000221,941,000294,337,000
Dividend
Jun 06, 20241.25 EUR/sh
Earnings
Feb 20, 2025

Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
URL
https://www.gerresheimer.com/
IPO date
Jun 11, 2007
Employees
11,234
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
1,990,486
9.54%
1,817,094
21.30%
Cost of revenue
1,784,757
1,901,175
Unusual Expense (Income)
NOPBT
205,729
(84,081)
NOPBT Margin
10.34%
Operating Taxes
47,344
38,620
Tax Rate
23.01%
NOPAT
158,385
(122,701)
Net income
116,126
20.81%
96,120
14.72%
Dividends
(45,298)
(39,250)
Dividend yield
Proceeds from repurchase of equity
271,610
BB yield
Debt
Debt current
382,813
535,717
Long-term debt
721,255
748,062
Deferred revenue
94,626
19,482
Other long-term liabilities
131,867
115,896
Net debt
966,493
1,144,143
Cash flow
Cash from operating activities
294,337
221,941
CAPEX
(328,037)
(238,074)
Cash from investing activities
(307,432)
(256,181)
Cash from financing activities
40,348
44,239
FCF
(122,454)
(322,852)
Balance
Cash
122,339
124,834
Long term investments
15,236
14,802
Excess cash
38,051
48,781
Stockholders' equity
742,410
755,548
Invested Capital
2,702,117
2,541,090
ROIC
6.04%
ROCE
7.21%
EV
Common stock shares outstanding
33,336
31,400
Price
Market cap
EV
EBITDA
391,755
87,474
EV/EBITDA
Interest
50,435
27,955
Interest/NOPBT
24.52%